59 related articles for article (PubMed ID: 33112553)
21. Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes.
Zhang W; Xie X; Mi H; Sun J; Ding S; Li L; Liu H; Wang H; Fu R; Shao Z
Oncol Lett; 2018 Apr; 15(4):5497-5504. PubMed ID: 29556297
[TBL] [Abstract][Full Text] [Related]
22. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
23. Harnessing NK Cell Memory for Cancer Immunotherapy.
Fehniger TA; Cooper MA
Trends Immunol; 2016 Dec; 37(12):877-888. PubMed ID: 27773685
[TBL] [Abstract][Full Text] [Related]
24. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.
Stringaris K; Marin D; Barrett AJ; Hills R; Sobieski C; Cao K; Saltarrelli JG; Daher M; Shaim H; Smith N; Linch D; Gale R; Allen C; Sekine T; Mehta R; Champlin R; Shpall EJ; Kantarjian H; Garcia-Manero G; Rezvani K
Blood; 2016 Dec; 128(24):2819-2823. PubMed ID: 27760759
[TBL] [Abstract][Full Text] [Related]
25. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
26. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
27. Bone Marrow Immunity and Myelodysplasia.
Lambert C; Wu Y; Aanei C
Front Oncol; 2016; 6():172. PubMed ID: 27489795
[TBL] [Abstract][Full Text] [Related]
28. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
[TBL] [Abstract][Full Text] [Related]
29. Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Sanchez-Correa B; Campos C; Pera A; Bergua JM; Arcos MJ; Bañas H; Casado JG; Morgado S; Duran E; Solana R; Tarazona R
Cancer Immunol Immunother; 2016 Apr; 65(4):453-63. PubMed ID: 26059279
[TBL] [Abstract][Full Text] [Related]
30. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida.
Valiathan R; Deeb K; Diamante M; Ashman M; Sachdeva N; Asthana D
Immunobiology; 2014 Jul; 219(7):487-96. PubMed ID: 24661720
[TBL] [Abstract][Full Text] [Related]
31. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
32. Revised international prognostic scoring system for myelodysplastic syndromes.
Greenberg PL; Tuechler H; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Malcovati L; Cazzola M; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres M; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D
Blood; 2012 Sep; 120(12):2454-65. PubMed ID: 22740453
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
Warlick ED; Miller JS
Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
[TBL] [Abstract][Full Text] [Related]
34. CD56bright natural killer (NK) cells: an important NK cell subset.
Poli A; Michel T; Thérésine M; Andrès E; Hentges F; Zimmer J
Immunology; 2009 Apr; 126(4):458-65. PubMed ID: 19278419
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function.
Marcondes AM; Mhyre AJ; Stirewalt DL; Kim SH; Dinarello CA; Deeg HJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):2865-70. PubMed ID: 18287021
[TBL] [Abstract][Full Text] [Related]
36. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
Epling-Burnette PK; Bai F; Painter JS; Rollison DE; Salih HR; Krusch M; Zou J; Ku E; Zhong B; Boulware D; Moscinski L; Wei S; Djeu JY; List AF
Blood; 2007 Jun; 109(11):4816-24. PubMed ID: 17341666
[TBL] [Abstract][Full Text] [Related]
37. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.
Fauriat C; Just-Landi S; Mallet F; Arnoulet C; Sainty D; Olive D; Costello RT
Blood; 2007 Jan; 109(1):323-30. PubMed ID: 16940427
[TBL] [Abstract][Full Text] [Related]
38. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.
Kiladjian JJ; Bourgeois E; Lobe I; Braun T; Visentin G; Bourhis JH; Fenaux P; Chouaib S; Caignard A
Leukemia; 2006 Mar; 20(3):463-70. PubMed ID: 16408099
[TBL] [Abstract][Full Text] [Related]
39. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia.
Costello RT; Sivori S; Marcenaro E; Lafage-Pochitaloff M; Mozziconacci MJ; Reviron D; Gastaut JA; Pende D; Olive D; Moretta A
Blood; 2002 May; 99(10):3661-7. PubMed ID: 11986221
[TBL] [Abstract][Full Text] [Related]
40. Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.
Aref S; Khaled N; Al Gilany AH; Ayed M; Abouzeid T; Attia D
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2949-2953. PubMed ID: 33112553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
